公开(公告)号：US20230141052A1

公开(公告)日：2023-05-11

申请号：US18157052

申请日：2023-01-19

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang ,  Namita Bisaria ,  Inna Shcherbakova ,  Socheata Ly

IPC: C12N15/85 ,  A61K31/713 ,  C12N15/90

CPC classification number: C12N15/85 ,  A61K31/713 ,  C12N15/90 ,  C07K2319/03 ,  C07K2319/09 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2310/20 ,  C12N2800/80 ,  C12N2800/90 ,  C12N2830/50 ,  C12N2840/203

Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.

公开(公告)号：US20210361703A1

公开(公告)日：2021-11-25

申请号：US17202018

申请日：2021-03-15

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang

IPC: A61K35/15 ,  C07K16/28 ,  C12N9/12 ,  C07K14/705 ,  C12N15/87 ,  A61P35/00 ,  C12N5/0786

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US20200345773A1

公开(公告)日：2020-11-05

申请号：US16827302

申请日：2020-03-23

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang

IPC: A61K35/15 ,  C07K16/28 ,  A61P35/00 ,  C07K14/705

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US20240391998A1

公开(公告)日：2024-11-28

申请号：US18674029

申请日：2024-05-24

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/735

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

公开(公告)号：US20230303684A1

公开(公告)日：2023-09-28

申请号：US18157643

申请日：2023-01-20

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang

IPC: C07K16/28 ,  C07K14/735 ,  A61P35/00

CPC classification number: C07K16/28 ,  C07K14/70535 ,  A61P35/00 ,  C07K2319/03 ,  C07K2317/565 ,  C07K2319/02 ,  C07K2317/622

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

公开(公告)号：US11628218B2

公开(公告)日：2023-04-18

申请号：US17590504

申请日：2022-02-01

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang ,  Bruce McCreedy, Jr.

IPC: A61K39/395 ,  A61K9/127 ,  A61P35/00 ,  A61K9/00 ,  A61K38/17

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

公开(公告)号：US20210299172A1

公开(公告)日：2021-09-30

申请号：US17209712

申请日：2021-03-23

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang

IPC: A61K35/15 ,  C07K14/705 ,  A61P35/00 ,  C07K16/28

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US10980836B1

公开(公告)日：2021-04-20

申请号：US16826708

申请日：2020-03-23

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang

IPC: A61K35/15 ,  C07K16/28 ,  C12N9/12 ,  C07K14/705 ,  C12N15/87 ,  A61P35/00 ,  C12N5/0786

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US20240327482A1

公开(公告)日：2024-10-03

申请号：US18600288

申请日：2024-03-08

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang ,  Bruce McCreedy, Jr.

IPC: C07K14/525 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K14/525 ,  C07K16/283 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/303 ,  C07K16/32 ,  C07K16/4291 ,  C07K2317/31 ,  C07K2319/30

Abstract: Compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.

公开(公告)号：US20240252630A1

公开(公告)日：2024-08-01

申请号：US18434220

申请日：2024-02-06

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang ,  Bruce McCreedy, Jr.

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K38/17 ,  A61K48/00 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/51 ,  A61K38/177 ,  A61K38/1774 ,  A61K48/005 ,  A61P35/00 ,  C07K2317/622 ,  C07K2319/00

Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.